重组人脑利钠肽治疗慢性心力衰竭的疗效观察  

Effect Observation on Recombinant human brain natriuretic peptide in the treatment of patients with chronic heart failure

作　　者：王斌[1] 李建民[1] 殷屹岗[1] 阮中宝[1] 顾爱琴[1] 

机构地区：[1]江苏省泰州市人民医院,江苏泰州225300

出　　处：《吉林医学》2015年第18期4034-4036,共3页Jilin Medical Journal

摘　　要：目的:观察重组人脑利钠肽(rhBNP)治疗慢性心力衰竭的临床疗效和安全性。方法:在标准抗心衰治疗的基础上,分别加用rhBNP和多巴酚丁胺,用药前及用药后,测定两组患者血脑钠肽、左室射血分数,重新评价患者心功能分级,观察两组患者3个月内主要心血管事件。结果:rhBNP能更好地改善慢性心力衰竭心功能,及血BNP水平的降低。治疗后,两组EF升高明显,但组间相比无显著性差异;有更多患者通过rhBNP治疗心功能改善达到NYHAⅡ级,差异有统计学意义(P<0.05)。3个月后随访,rhBNP组与多巴酚丁胺组患者的主要心血管事件差异无统计学意义。结论:与多巴酚丁胺比较,rhBNP能更好地改善慢性心率衰竭患者心功能,但对预后的改善未见明显差异。Objective To observe clinical efficacy and safety of the recombinant human brain natriuretic peptide（rhBNP）in the treat-ment of chronic heart failure. Method On the basis of standard heart failure therapy,combined with rhBNP and dobutamine therapy,The blood BNP,left ventricular ejection fraction（EF% ）were determined before and after treatment,cardiac function of the patients were re -evaluation by NYHA. To observe two groups of patients with major cardioascular events in three months. Results rhBNP could better im-prove cardiac function in chronic heart failure,and lower blood BNP level. After treatment,two groups of EF rose significantly,but com-pared between groups had no significant difference;More patients treated by rhBNP cardiac function improvement to NYHA Ⅱ level,the difference was statistically significant（P ﹤ 0. 05）. After three months,in the rhBNP and dobutamine group major cardiovascular events of patients with no statistically significant difference. Conclusion Compared with dobutamine,rhBNP can better improve cardiac function in patients with chronic heart failure,but no significant difference on the improvement of the prognosis.

关 键 词：重组人脑利钠肽 多巴酚丁胺 心力衰竭 疗效 

分 类 号：R541.6[医药卫生—心血管疾病]